|Other Names||Apoptosis regulator Bcl-2, BCL2|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13823c was selected from the Center region of BCL2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1).|
|Cellular Location||Mitochondrion outer membrane; Single-pass membrane protein. Nucleus membrane; Single-pass membrane protein. Endoplasmic reticulum membrane; Single-pass membrane protein|
|Tissue Location||Expressed in a variety of tissues.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes an integral outer mitochondrial membraneprotein that blocks the apoptotic death of some cells such aslymphocytes. Constitutive expression of BCL2, such as in the caseof translocation of BCL2 to Ig heavy chain locus, is thought to bethe cause of follicular lymphoma. Two transcript variants, producedby alternate splicing, differ in their C-terminal ends. [providedby RefSeq].
Feng, H., et al. Cancer Cell 18(4):353-366(2010)Azad, N., et al. Ann. N. Y. Acad. Sci. 1203, 1-6 (2010) :Dubikov, A.I., et al. Scand. J. Rheumatol. 39(5):368-372(2010)Yu, B., et al. J. Exp. Clin. Cancer Res. 29, 107 (2010) :Trisciuoglio, D., et al. PLoS ONE 5 (7), E11772 (2010) :
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.